Japan Antiphospholipid syndrome-Stroke Prevention Study

Japan Antiphospholipid syndrome-Stroke Prevention Study - JASPRES

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000342

Enrollment

100

Registered

2006-03-01

Start date

2006-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiphospholipid syndrome

Interventions

Warfarin, INR 2.0, 2 years cilostazol, 200mg/day, 2 years or ticlopidine, 100-200mg/day, 2 years

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with antiphospholipid syndrome who fulfil the Sapporo Criteria and have cerebral infarct

Exclusion criteria

Exclusion criteria: Female patients who are pregnant or plans to be pregnant Patients who cannot have warfarin or antiplatetet drugs Patients who are required to take warfarin Patients with severe hepatic, renal or cardiac failure Other inadequate patients for this clinical trial

Design outcomes

Primary

Measure	Time frame
Cerebral Infarct Score in MRI	—

Countries

Japan

Contacts

Public ContactTatsuya Atsumi

Hokkaido University Hospital Medicine II

at3tat@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026